Skip to content

FDA approves acalabrutinib plus venetoclax for CLL, SLL
Clinical trial criteria exclude over 40% of real-world patients with AL amyloidosis
Prof. Charles Craddock, CBE, discusses paradigm trial, transplant advances at ASH 2025
Assay targeting KMT2A rearrangements in AML now available
FDA issues draft guidance on MRD, CR endpoints in MM clinical trials

Join SOHO

Follow Us :

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

Elias Jabbour, MD

Cellular Therapy

Elias Jabbour, MD

Leukemia

Elias Jabbour, MD

Lymphoma

Elias Jabbour, MD

Multiple Myeloma

Elias Jabbour, MD

Myelodysplastic Syndromes

Elias Jabbour, MD

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

February 21, 2026

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

SOHO Insider Elias Jabbour, MD

Elias Jabbour, MD

by sohonews
October 16, 2024
0 Comments
Less than a minute
472 Views
1 year ago

Share This Post:

Facebook Twitter Pinterest Whatsapp Cloud StumbleUpon Print Share via Email

Related Post

FDA

Leukemia, Chronic Lymphocytic Leukemia, Lymphoma, Indolent B-Cell Lymphomas, News

FDA approves acalabrutinib plus venetoclax for CLL, SLL

February 20, 2026

Multiple Myeloma

Clinical trial criteria exclude over 40% of real-world patients

February 19, 2026

Charles Craddock

ASH 2025, Acute Myeloid Leukemia, News

Prof. Charles Craddock, CBE, discusses paradigm trial, transplant advances

February 17, 2026

Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, News

Assay targeting KMT2A rearrangements in AML now available

February 16, 2026

FDA editorial

Multiple Myeloma, News

FDA issues draft guidance on MRD, CR endpoints in

February 16, 2026

SOHO Insider podcast

Past Sessions, Trending now, Community Oncology, Cellular Therapy, Lymphoma, News, Video Interviews

Dr. Tara Graff presents ‘Implementing bispecific antibodies in community

February 15, 2026

Top Categories

Cellular Therapy

49

Leukemia

83

Lymphoma

89

Multiple Myeloma

77

Myelodysplastic Syndromes

28

Myeloproliferative Neoplasms

18

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Elias Jabbour, MD

Cellular Therapy

Elias Jabbour, MD

Leukemia

Elias Jabbour, MD

Lymphoma

Elias Jabbour, MD

Multiple Myeloma

Elias Jabbour, MD

Myelodysplastic Syndromes

Elias Jabbour, MD

Myeloproliferative Neoplasms

Subscribe

Recent Posts

FDA

FDA approves acalabrutinib plus venetoclax for CLL, SLL

Clinical trial criteria exclude over 40% of real-world patients with AL amyloidosis

Charles Craddock

Prof. Charles Craddock, CBE, discusses paradigm trial, transplant advances at ASH 2025

Copyright © 2026 Society of Hematologic Oncology, All rights reserved.